EP35 SHOULD MODEL FOR END STAGE LIVER DISEASES (MELD) AND MELD-BASED SCORES BE ROUTINELY APPLIED TO PREOPERATIVE ASSESMENT OF PATIENT UNDERGOING VALVULAR CARDIAC SURGERY?

2018 ◽  
Vol 19 ◽  
pp. e37
Author(s):  
A. Celentano ◽  
L.J.T. Masiglat ◽  
S. Pelenghi ◽  
P. Totaro
2006 ◽  
Vol 54 (S 1) ◽  
Author(s):  
T Krabatsch ◽  
M Bechtel ◽  
C Detter ◽  
T Fischlein ◽  
FC Riess ◽  
...  

PLoS ONE ◽  
2012 ◽  
Vol 7 (3) ◽  
pp. e31256 ◽  
Author(s):  
Ming Zhang ◽  
Fei Yin ◽  
Bo Chen ◽  
You Ping Li ◽  
Lu Nan Yan ◽  
...  

2021 ◽  
Vol 28 ◽  
Author(s):  
Xiaohong Li ◽  
Liang Wen ◽  
Jiao Liu ◽  
Xiaohong Wang

: End-stage liver diseases have long been a threat to human health, and so far, the treatment of these diseases lacks of effective means. Allogenic organ transplantation has become the last straw for most of the patients with end-stage liver diseases. However, this technique has been greatly limited by the serious shortage of donors and other factors, such as immune rejection, drug syndrome, and high cost. Recently, the emergence of three-dimensional (3D) bioprinting technologies, together with the magnetic resonance imaging (MRI) and computed tomography (CT) techniques, has driven the rapid growth of this field toward liver therapies. There are several basic requirements for liver 3D bioprinting. From information collection of diseased livers, to 3D printing of liver substitutes (containing the major structural, material and functional characters), and to clinical applications, suitable ‘bioinks’ and ‘bioprinters’ have played essential roles. In this review, we highlight the advanced ‘bioinks’ and ‘bioprinters’ that have been used for vascularized and innervated liver tissue 3D bioprinting. Further studies for the incorporation of biliary networks in the bioartificial livers have been emphasized. It is expected that when all the bottle-neck problems for liver 3D bioprinting are solved, batch (i.e. mass) and personalized production of bioartificial livers will make it very easy to treat end-stage liver diseases.


2021 ◽  
Vol 22 (19) ◽  
pp. 10276
Author(s):  
Julia Hofmann ◽  
Verena Hackl ◽  
Hannah Esser ◽  
Andras T. Meszaros ◽  
Margot Fodor ◽  
...  

The liver, in combination with a functional biliary system, is responsible for maintaining a great number of vital body functions. However, acute and chronic liver diseases may lead to irreversible liver damage and, ultimately, liver failure. At the moment, the best curative option for patients suffering from end-stage liver disease is liver transplantation. However, the number of donor livers required by far surpasses the supply, leading to a significant organ shortage. Cellular therapies play an increasing role in the restoration of organ function and can be integrated into organ transplantation protocols. Different types and sources of stem cells are considered for this purpose, but highly specific immune cells are also the focus of attention when developing individualized therapies. In-depth knowledge of the underlying mechanisms governing cell differentiation and engraftment is crucial for clinical implementation. Additionally, novel technologies such as ex vivo machine perfusion and recent developments in tissue engineering may hold promising potential for the implementation of cell-based therapies to restore proper organ function.


2021 ◽  
Vol 12 ◽  
Author(s):  
Arzoo M. Patel ◽  
Yuxin S. Liu ◽  
Scott P. Davies ◽  
Rachel M. Brown ◽  
Deirdre A. Kelly ◽  
...  

B lymphocytes are multitasking cells that direct the immune response by producing pro- or anti-inflammatory cytokines, by presenting processed antigen for T cell activation and co-stimulation, and by turning into antibody-secreting cells. These functions are important to control infection in the liver but can also exacerbate tissue damage and fibrosis as part of persistent inflammation that can lead to end stage disease requiring a transplant. In transplantation, immunosuppression increases the incidence of lymphoma and often this is of B cell origin. In this review we bring together information on liver B cell biology from different liver diseases, including alcohol-related and metabolic fatty liver disease, autoimmune hepatitis, primary biliary and primary sclerosing cholangitis, viral hepatitis and, in infants, biliary atresia. We also discuss the impact of B cell depletion therapy in the liver setting. Taken together, our analysis shows that B cells are important in the pathogenesis of liver diseases and that further research is necessary to fully characterise the human liver B cell compartment.


2021 ◽  
Vol 11 (1) ◽  
pp. 202-212
Author(s):  
Michal Szlapka ◽  
Roland Hetzer ◽  
Jürgen Ennker ◽  
Harald Hausmann

2019 ◽  
Vol 51 (11) ◽  
pp. 1513-1514 ◽  
Author(s):  
Maria Rendina ◽  
Maria Teresa Viggiani ◽  
Alfredo Di Leo ◽  
Michele Barone

Sign in / Sign up

Export Citation Format

Share Document